Top

Published in:

01-04-2019 | Lymphoma | Original Article

The role of ABCB1 polymorphism as a prognostic marker for primary central nervous system lymphoma

Authors: Ting Wu, Hui Kang, Dongxiao Zhuang, Yan Ma, Zhiguang Lin, Dina Suolitiken, Bobin Chen, Xiaoping Xu

Published in: Annals of Hematology | Issue 4/2019

Abstract

To investigate the possible role of functional single nucleotide polymorphism (SNP) in circadian genes as prognostic markers of primary central nervous system lymphoma (PCNSL). We conducted a prospective study using data from Huashan Hospital 2006–2015 and followed up 91 PCNSL patients until June 30, 2016. The survival of patients with different prognostic factors was compared by log-rank test. Univariate and multivariate analyses were performed by Cox regression. During a long-term follow-up (6–110 months), overall survival (OS) was 32 months (95% CI, 13.3–91.1) and progression-free survival (PFS) was 23 months (95% CI, 9.0–41.0) for the entire cohort. Age (P = 0.046, P = 0.001) and performance status (PS) score (P = 0.013, P = 0.003) showed differences in OS and PFS. ABCB1 rs1045642 variant showed significant difference in PFS between patients with CC genotype and those with CT/TT genotypes (P = 0.020). In multivariate analysis, age (HR = 2.3; 95% CI, 1.2–4.2, P = 0.008), PS (HR = 2.4; 95% CI, 1.3–4.4, P = 0.007), and ABCB1 rs1045642 (HR = 1.9; 95% CI, 1.0–3.3, P = 0.036) were the independent risk factors for PFS. In our results, the most important prognostic factors associated with higher risk of progression were ABCB1 rs1045642 CC genotype, PS > 2, and older age.

Available only for authorised users

Dolecek TA, Propp JM, Stroup NE, Kruchko C (2012) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro-Oncology 14(Suppl 5):v1–v49. https://doi.org/10.1093/neuonc/nos218 CrossRefPubMedPubMedCentral

Camilleri-Broet S, Criniere E, Broet P, Delwail V, Mokhtari K, Moreau A, Kujas M, Raphael M, Iraqi W, Sautes-Fridman C, Colombat P, Hoang-Xuan K, Martin A (2006) A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. Blood 107(1):190–196. https://doi.org/10.1182/blood-2005-03-1024 CrossRefPubMed

Carbone A, Gloghini A, Larocca LM, Capello D, Pierconti F, Canzonieri V, Tirelli U, Dalla-Favera R, Gaidano G (2001) Expression profile of MUM1/IRF4, BCL-6, and CD138/syndecan-1 defines novel histogenetic subsets of human immunodeficiency virus-related lymphomas. Blood 97(3):744–751CrossRefPubMed

Kreher S, Johrens K, Strehlow F, Martus P, Borowiec K, Radke J, Heppner F, Roth P, Thiel E, Pietsch T, Weller M, Korfel A (2015) Prognostic impact of B-cell lymphoma 6 in primary CNS lymphoma. Neuro-Oncology 17(7):1016–1021. https://doi.org/10.1093/neuonc/nov046 CrossRefPubMedPubMedCentral

Ferreri AJ, Blay JY, Reni M, Pasini F, Spina M, Ambrosetti A, Calderoni A, Rossi A, Vavassori V, Conconi A, Devizzi L, Berger F, Ponzoni M, Borisch B, Tinguely M, Cerati M, Milani M, Orvieto E, Sanchez J, Chevreau C, Dell’Oro S, Zucca E, Cavalli F (2003) Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol 21(2):266–272CrossRefPubMed

Abrey LE, Ben-Porat L, Panageas KS, Yahalom J, Berkey B, Curran W, Schultz C, Leibel S, Nelson D, Mehta M, DeAngelis LM (2006) Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol 24(36):5711–5715. https://doi.org/10.1200/jco.2006.08.2941 CrossRefPubMed

Roth P, Keller A, Hoheisel JD, Codo P, Bauer AS, Backes C, Leidinger P, Meese E, Thiel E, Korfel A, Weller M (2015) Differentially regulated miRNAs as prognostic biomarkers in the blood of primary CNS lymphoma patients. Eur J Cancer 51(3):382–390. https://doi.org/10.1016/j.ejca.2014.10.028 CrossRefPubMed

Mao X, Sun Y, Tang J (2014) Serum miR-21 is a diagnostic and prognostic marker of primary central nervous system lymphoma. Neurol Sci 35(2):233–238. https://doi.org/10.1007/s10072-013-1491-9 CrossRefPubMed

Kasenda B, Haug V, Schorb E, Fritsch K, Finke J, Mix M, Hader C, Weber WA, Illerhaus G, Meyer PT (2013) 18F-FDG PET is an independent outcome predictor in primary central nervous system lymphoma. J Nucl Med 54(2):184–191. https://doi.org/10.2967/jnumed.112.108654 CrossRefPubMed

10.

Lee KM, Lan Q, Kricker A, Purdue MP, Grulich AE, Vajdic CM, Turner J, Whitby D, Kang D, Chanock S, Rothman N, Armstrong BK (2007) One-carbon metabolism gene polymorphisms and risk of non-Hodgkin lymphoma in Australia. Hum Genet 122(5):525–533. https://doi.org/10.1007/s00439-007-0431-2 CrossRefPubMed

11.

Wang SS, Maurer MJ, Morton LM, Habermann TM, Davis S, Cozen W, Lynch CF, Severson RK, Rothman N, Chanock SJ, Hartge P, Cerhan JR (2009) Polymorphisms in DNA repair and one-carbon metabolism genes and overall survival in diffuse large B-cell lymphoma and follicular lymphoma. Leukemia 23(3):596–602. https://doi.org/10.1038/leu.2008.240 CrossRefPubMed

12.

Al-Dayel F, Al-Rasheed M, Ibrahim M, Bu R, Bavi P, Abubaker J, Al-Jomah N, Mohamed GH, Moorji A, Uddin S, Siraj AK, Al-Kuraya K (2008) Polymorphisms of drug-metabolizing enzymes CYP1A1, GSTT and GSTP contribute to the development of diffuse large B-cell lymphoma risk in the Saudi Arabian population. Leuk Lymphoma 49(1):122–129. https://doi.org/10.1080/10428190701704605 CrossRefPubMed

13.

Gra OA, Glotov AS, Nikitin EA, Glotov OS, Kuznetsova VE, Chudinov AV, Sudarikov AB, Nasedkina TV (2008) Polymorphisms in xenobiotic-metabolizing genes and the risk of chronic lymphocytic leukemia and non-Hodgkin’s lymphoma in adult Russian patients. Am J Hematol 83(4):279–287. https://doi.org/10.1002/ajh.21113 CrossRefPubMed

14.

Morton LM, Schenk M, Hein DW, Davis S, Zahm SH, Cozen W, Cerhan JR, Hartge P, Welch R, Chanock SJ, Rothman N, Wang SS (2006) Genetic variation in N-acetyltransferase 1 (NAT1) and 2 (NAT2) and risk of non-Hodgkin lymphoma. Pharmacogenet Genomics 16(8):537–545. https://doi.org/10.1097/01.fpc.0000215071.59836.29 CrossRefPubMedPubMedCentral

15.

Cerhan JR, Habermann TM, Maurer MJ, Wooldridge JE, Ansell SM, Nowakowski GS, Micallef IN, Thompson CA, Wang AH, Macon WR, Syrbu SI, Slager SL, Witzig TE, Link B (2010) Genetic polymorphisms in genes involved in R-CHOP metabolism and event-free and overall survival in diffuse large B-cell lymphoma. Blood 116(21):439–439

16.

Chen BB, Xu XP, Shen L, Han TJ, Lin ZG, Chen Z, Kang H, Huang B, Lin GW (2013) Prognostic value of clinical characteristics and immunophenotypic biomarkers in 115 patients with primary central nervous system lymphoma. Chin Med J 126(3):482–487PubMed

17.

Aller SG, Yu J, Ward A, Weng Y, Chittaboina S, Zhuo R, Harrell PM, Trinh YT, Zhang Q, Urbatsch IL, Chang G (2009) Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science (New York, NY) 323(5922):1718–1722. https://doi.org/10.1126/science.1168750 CrossRef

18.

Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV, Gottesman MM (2007) A “silent” polymorphism in the MDR1 gene changes substrate specificity. Science (New York, NY) 315(5811):525–528. https://doi.org/10.1126/science.1135308 CrossRef

19.

Bogacz A, Mrozikiewicz PM, Deka-Pawlik D, Seremak-Mrozikiewicz A, Bartkowiak-Wieczorek J, Barlik M, Drews K, Kowalska A, Grzeskowiak E (2013) Frequency of G2677T/A and C3435T polymorphisms of MDR1 gene in preeclamptic women. Ginekol Pol 84(9):781–787CrossRefPubMed

20.

Vinolas N, Provencio M, Reguart N, Cardenal F, Alberola V, Sanchez-Torres JM, Baron FJ, Cobo M, Maestu I, Moreno I, Mesia C, Izquierdo A, Felip E, Lopez-Brea M, Marquez A, Sanchez-Ronco M, Taron M, Santarpia MC, Rosell R (2011) Single nucleotide polymorphisms in MDR1 gen correlates with outcome in advanced non-small-cell lung cancer patients treated with cisplatin plus vinorelbine. Lung Cancer (Amsterdam, Netherlands) 71(2):191–198. https://doi.org/10.1016/j.lungcan.2010.05.005 CrossRef

21.

Ma CX, Sun YH, Wang HY (2015) ABCB1 polymorphisms correlate with susceptibility to adult acute leukemia and response to high-dose methotrexate. Tumour Biol 36(10):7599–7606. https://doi.org/10.1007/s13277-015-3403-5 CrossRefPubMed

22.

Li Y, Yan PW, Huang XE, Li CG (2011) MDR1 gene C3435T polymorphism is associated with clinical outcomes in gastric cancer patients treated with postoperative adjuvant chemotherapy. Asian Pac J Cancer Prev 12(9):2405–2409PubMed

23.

Wang Z, Wang T, Bian J (2013) Association between MDR1 C3435T polymorphism and risk of breast cancer. Gene 532(1):94–99. https://doi.org/10.1016/j.gene.2013.09.050 CrossRefPubMed

24.

Ni Y, Yin G, Xiao Z, Fan L, Wang L, Wu Y, Wu H, Qian S, Xu W, Li J, Miao K, Qiu H (2016) MDR1 polymorphisms have an impact on the prognosis of Chinese diffuse large B cell lymphoma patients. Tumour Biol 37(1):1237–1244. https://doi.org/10.1007/s13277-015-3930-0 CrossRefPubMed

25.

Gregers J, Green H, Christensen IJ, Dalhoff K, Schroeder H, Carlsen N, Rosthoej S, Lausen B, Schmiegelow K, Peterson C (2015) Polymorphisms in the ABCB1 gene and effect on outcome and toxicity in childhood acute lymphoblastic leukemia. Pharmacogenomics J 15(4):372–379. https://doi.org/10.1038/tpj.2014.81 CrossRefPubMedPubMedCentral

26.

Yang YL, Lin DT, Chang SK, Lin SR, Lin SW, Chiou RJ, Yen CT, Lin KH, Jou ST, Lu MY, Chang HH, Chang WH, Lin KS, Hu CY (2010) Pharmacogenomic variations in treatment protocols for childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 54(2):206–211. https://doi.org/10.1002/pbc.22292 CrossRefPubMed

27.

Rao DN, Anuradha C, Vishnupriya S, Sailaja K, Surekha D, Raghunadharao D, Rajappa S (2010) Association of an MDR1 gene (C3435T) polymorphism with acute leukemia in India. Asian Pac J Cancer Prev 11(4):1063–1066PubMed

28.

Jamroziak K, Mlynarski W, Balcerczak E, Mistygacz M, Trelinska J, Mirowski M, Bodalski J, Robak T (2004) Functional C3435T polymorphism of MDR1 gene: an impact on genetic susceptibility and clinical outcome of childhood acute lymphoblastic leukemia. Eur J Haematol 72(5):314–321. https://doi.org/10.1111/j.1600-0609.2004.00228.x CrossRefPubMed

29.

Kishi S, Cheng C, French D, Pei D, Das S, Cook EH, Hijiya N, Rizzari C, Rosner GL, Frudakis T, Pui CH, Evans WE, Relling MV (2007) Ancestry and pharmacogenetics of antileukemic drug toxicity. Blood 109(10):4151–4157. https://doi.org/10.1182/blood-2006-10-054528 CrossRefPubMedPubMedCentral

30.

Suthandiram S, Gan GG, Zain SM, Bee PC, Lian LH, Chang KM, Ong TC, Mohamed Z (2014) Effect of polymorphisms within methotrexate pathway genes on methotrexate toxicity and plasma levels in adults with hematological malignancies. Pharmacogenomics 15(11):1479–1494. https://doi.org/10.2217/pgs.14.97 CrossRefPubMed

31.

Dervieux T, Greenstein N, Kremer J (2006) Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis. Arthritis Rheum 54(10):3095–3103. https://doi.org/10.1002/art.22129 CrossRefPubMed

32.

Organista-Nava J, Gomez-Gomez Y, Saavedra-Herrera MV, Rivera-Ramirez AB, Teran-Porcayo MA, Alarcon-Romero Ldel C, Illades-Aguiar B, Leyva-Vazquez MA (2010) Polymorphisms of the gamma-glutamyl hydrolase gene and risk of relapse to acute lymphoblastic leukemia in Mexico. Leuk Res 34(6):728–732. https://doi.org/10.1016/j.leukres.2009.11.027 CrossRefPubMed

33.

Garcia-Bournissen F, Moghrabi A, Krajinovic M (2007) Therapeutic responses in childhood acute lymphoblastic leukemia (ALL) and haplotypes of gamma glutamyl hydrolase (GGH) gene. Leuk Res 31(7):1023–1025. https://doi.org/10.1016/j.leukres.2006.08.007 CrossRefPubMed

Title: The role of ABCB1 polymorphism as a prognostic marker for primary central nervous system lymphoma
Authors: Ting Wu
Hui Kang
Dongxiao Zhuang
Yan Ma
Zhiguang Lin
Dina Suolitiken
Bobin Chen
Xiaoping Xu
Publication date: 01-04-2019
Publisher: Springer Berlin Heidelberg
Keywords: Lymphoma
Diffuse Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma
Published in: Annals of Hematology / Issue 4/2019
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-019-03629-7

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2019

Role of platelets in thrombin generation amongst patients with non-transfusion-dependent thalassaemia

Long-term response to daratumumab in a patient with advanced immunoglobulin light-chain (AL) amyloidosis with organ damage

Anti-glomerular basement membrane disease due to monoclonal IgG Lambda antibodies: a very rare case of monoclonal gammopathy of renal significance

Deciphering the prognostic significance of autoimmune disorders in myelodysplastic syndromes

High-dose etoposide could discriminate the benefit from autologous peripheral blood stem cell transplantation in the patients with refractory diffuse large B cell lymphoma

The burden of psychiatric illnesses in adult patients with beta-thalassemia: a 5-year nationwide inpatient evaluation in the United States

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials